17 February 2023 in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
Advance consent presents a potential solution to the challenge of obtaining informed consent for participation in acute stroke trials. Clinicians in stroke prevention clinics are uniquely positioned to identify and seek consent from potential stroke trial participants. To assess the acceptability of advance consent to Canadian stroke clinic physicians, we performed an online survey. We obtained 58 respondents (response rate 35%): the vast majority (82%) expressed comfort with obtaining advance consent and 92% felt that doing so would not be a significant disruption to clinic workflow. These results support further study of advance consent for acute stroke trials. RÉSUMÉ : Consentement préalable et essais cliniques portant sur les AVC aigus : un sondage mené auprès de médecins canadiens spécialistes de l’AVC. Le consentement préalable constitue une solution potentielle au problème de l’obtention d’un consentement éclairé en ce qui regarde la participation à des essais cliniques portant sur les AVC aigus. À cet égard, les cliniciens qui œuvrent au sein des cliniques de prévention des AVC sont particulièrement bien placés pour identifier des patients potentiels à de tels essais et obtenir leur consentement. Pour évaluer l’acceptabilité du consentement préalable parmi les médecins des cliniques canadiennes spécialisées dans les AVC, nous avons effectué un sondage en ligne. Nous avons ainsi obtenu 58 réponses (taux de réponse : 35 %). À noter que la grande majorité des répondants (82 %) s’est dite à l’aise avec l’obtention d’un consentement préalable tandis que 92 % d’entre eux ont estimé que cette démarche ne perturberait pas de manière significative le flux de travail dans leur établissement. Ces résultats soutiennent donc la poursuite d’études portant sur le consentement préalable et des essais cliniques dans le cas d’AVC aigus.
24 July 2023 in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
Advance consent could allow individuals at high risk of stroke to provide consent before they might become eligible for enrollment in acute stroke trials. This survey explores the acceptability of this novel technique to Canadian Research Ethics Board (REB) chairs that review acute stroke trials. Responses from 15 REB chairs showed that majority of respondents expressed comfort approving studies that adopt advance consent. There was no clear preference for advance consent over deferral of consent, although respondents expressed significant concern with broad rather than trial-specific advance consent. These findings shed light on the acceptability of advance consent to Canadian ethics regulators.
15 October 2024 in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
Advance consent could address many of the limitations traditional consenting methods pose to participation in acute stroke trials. We conducted a series of five focus groups with people with lived experience of stroke. Using an inductive thematic approach, two themes were developed: factors in favour of, and against, advance consent. Participants supported the idea of advance consent and highlighted trust, transparent communication and sufficient time as major factors that would positively affect their decision to provide advance consent. The results will be used to finalise a model of advance consent suitable for testing the feasibility in stroke prevention clinics.
2 October 2024 in Stroke and Vascular Neurology
Introduction Obtaining informed consent for research from patients in medical emergencies remains a challenge, particularly in acute stroke care as treatment must be administered quickly and patients often arrive in the hospital in a state of incapacitation. Adaptations to standard consenting approaches—such as the use of surrogate consent or deferral of consent—have significant limitations. This feasibility study aims to test a new consenting approach in acute stroke care that we call advance consent. Advance consent has the potential to render emergency trial enrolment faster, fairer and more transparent, leading to more generalisable results. Methods and design We will conduct a five-part study at The Ottawa Hospital, a quaternary care stroke centre: (1) administering questionnaires in the Ottawa Hospital Stroke Prevention Clinic that will examine patients’ perspectives on research participation and advance consent; (2) inviting participants to consent in advance to any or both currently enrolling acute stroke trials; (3) tracking patient enrolment into these trials over 1 year; (4) administering a follow up questionnaire to participants at 1 year and (5) administering a questionnaire to participating hospital staff in order to interrogate their experiences with advance consent. Outcomes include but are not limited to eligibility rate, recruitment rate, withdrawal rate and the proportion of patients whose advance consent results in trial enrolment. Conclusion This study will test the feasibility of enrolling patients at risk of stroke into acute stroke trials using advance consent.
24 April 2026 in Journal of Clinical Epidemiology
Launched in August 2024, the ACT-GLOBAL (A multi-faCtorial, mulTi-arm, multi-staGe, randomised, gLOBal Adaptive pLatform) trial is the first multinational adaptive platform trial for acute stroke. Because it proposes to enroll participants by deferral of consent, the ACT-GLOBAL trial seeks to publish an explicit justification for this practice. Following a standardized protocol for establishing whether it is justified to use deferral of consent, all active domains of the ACT-GLOBAL platform adaptive trial were considered according to six questions: 1. Is there evidence-based uncertainty about the research question; 2. Is the standard of care treatment included in the trial, meaning that patients are unlikely to be disadvantaged by their participation?; 3. Is the trial of sufficient methodological rigour that it can result in a change of practice?; 4. Are Patients Eligible for Enrollment in the Trial Likely to be Incapable of Providing Their Own Consent? 5. Will Seeking to Obtain Consent from a Surrogate Decision-Maker Meaningfully Delay Treatment and Impact Outcomes? ; And 6. Are Steps Taken to Mitigate the Compromise to Individual Autonomy? The leadership of the ACT-GLOBAL trial are able to answer affirmatively the six questions outlined above in relation to each of the trial's current domains. The results of this analysis suggest that the use of deferral of consent in the ACT-GLOBAL trial is ethically justified, where permitted by law. This exercise demonstrates the utility of following an accepted protocol for determining whether alterations to standard consent practices such as deferral of consent are ethically justified in acute stroke research.
14 October 2026 in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques